11 December 2024 Corporate Press Release Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer 9 December 2024
Results from the investigational, pivotal Phase III PACIFIC trial showing statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with IMFINZI®(durvalumab) in patients with locally-advanced (Stage III), unresectable non-small cell ...
AstraZeneca Oncology business unit executive vice-president Dave Fredrickson said: “Today’s approval of Imfinzi plus chemotherapy brings an important global standard of care to patients with extensive-stage small-cell lung cancer in China, who have had few treatment options and a dire prognosis. ...
AstraZeneca , a science-led , patient focused pharmaceutical company , and AC Health , a healthcare corporation with a portfolio that includes hospitals , clinics and digital health , have partnered to push for early screening for lung cancer utilizing AI through the Lung Ambition Alliance . ...
Data will also be presented from the PACIFIC and CASPIAN Phase III trials highlighting the long-term benefit of IMFINZI®across different types of lung cancer. These include a presentation of four-year OS data in patients with unresectable ...
The US FDA has granted approval for Daiichi Sankyo and AstraZeneca’s Enhertu to treat unresectable or metastatic non-small cell lung cancer.
AstraZeneca boasts a strong position in cancer, led by lung cancer drug Tagrisso, PARP inhibitor Lynparza and PD-L1 agent Imfinzi. It also sells products in cardiovascular, renal and metabolic diseases. The company recently pivoted to develop a COVID-19 vaccine,AZD1222, in a partnership with...
Driving Progress in GI Cancers,” based on data from both the DESTINY-CRC01 and DESTINY-Gastric01 trials, as well as one of the targeted therapy advances of the year in non-small cell lung cancer (NSCLC), based on the interim resu...
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumo...
Dave Fredrickson, executive vice president, oncology business unit, said: “For the first time, a targeted, biomarker-driven treatment option is available to patients in the US with early-stage EGFR-mutated lung cancer. This approval dispels the notion that treatment is over after surgery and ch...